TY - JOUR AU - Giardina, A.R. AU - Accardo-Palumbo, A. AU - Ciccia, F. AU - Ferrante, A. AU - Principato, A. AU - Impastato, R. AU - Triolo, G. PY - 2009/03/30 Y2 - 2024/03/29 TI - Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vγ9/Vδ2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis? JF - Reumatismo JA - Reumatismo VL - 61 IS - 1 SE - Articles DO - 10.4081/reumatismo.2009.21 UR - https://www.reumatismo.org/reuma/article/view/reumatismo.2009.21 SP - 21-26 AB - Biological therapeutic agents neutralising tumour necrosis factor (TNF) are highly active in treating chronic inflammatory diseases, such as Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, uveitis, and psoriasis (1-3). From the beginning, side effects of TNF neutralisation - mostly infectious complications - were recognized, the most important being, however, pulmonary tuberculosis infections (4). ER -